Medline ® Abstract for Reference 61
of 'Management of gastrointestinal lymphomas'
Combination chemotherapy for primary small intestinal lymphoma in the Middle East.
el Saghir NS, Jessen K, Mass RE, al-Mofleh I, Santhosh-Kumar CR, Hall AD, Stuart AE
Eur J Cancer Clin Oncol. 1989;25(5):851.
Twelve patients with primary small intestinal lymphoma were followed prospectively for 3 years. Endoscopic abnormalities were diagnostic of lymphoma in all cases where the duodenum was involved (83%). In three cases (25%) the disease extended to the stomach. One patient (8%) had diffuse small cell cleaved and 11 (92%) diffuse large cell lymphoma stages I (8%), II (25%), III (58%) and IV (8%). Nine of them were unresectable and primarily treated with combination chemotherapy; 67% achieved complete remission, 22% partial response and 11% no response. Only one patient relapsed and achieved a second remission. All complete remission patients are currently alive and free of disease at a median follow-up of 36 months. Overall survival for all patients is 58%, and disease-free survival is 50%. No instance of chemotherapy-related bleeding or perforation was seen. Tetracycline was necessary for the treatment of IPSID-associated diarrhea and malabsorption in spite of cytotoxic chemotherapy.
King Saud University College of Medicine, Riyadh, Saudi Arabia.